SCHEMBL6577060

SCHEMBL6577060

COC(=O)[C@H](Cc1ccc(OCc2ccccc2)cc1)NS(C)(=O)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.60
LTA4H P09960 1/20 0.60
POLB P06746 1/20 0.57
CA12 O43570 2/20 0.55
CA7 P43166 2/20 0.55
CA9 Q16790 2/20 0.55
CA14 Q9ULX7 2/20 0.55
CA2 P00918 1/20 0.55
ITGB3 P05106 1/20 0.54
ITGA2B P08514 1/20 0.54
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
AR P10275 1/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GAA P10253 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27466542 1.00 PPARG (0.60) PPARGLTA4HPOLBCA12CA7
SCHEMBL6435869 0.88 POLB (0.69) POLBCA12CA7CA9CA14
SCHEMBL20334978 0.88 POLB (0.69) POLBCA12CA7CA9CA14
SCHEMBL6435872 0.88 POLB (0.69) POLBCA12CA7CA9CA14
SCHEMBL3499760 0.85 LTA4H (0.65) PPARGLTA4HRAB9ANPC1SMN1; SMN2
SCHEMBL13110180 0.85 LTA4H (0.65) PPARGLTA4HRAB9AGAAMEN1
SCHEMBL3499757 0.85 LTA4H (0.65) PPARGLTA4HRAB9ANPC1SMN1; SMN2
SCHEMBL8762284 0.84 AR (0.58) PPARGLTA4HPOLBITGB3ITGA2B
Hydrochloric Acid SCHEMBL29693844 0.84 LTA4H (0.64) PPARGLTA4HRAB9AGAAMEN1
SCHEMBL9819677 0.83 POLB (0.55) POLBCA12CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1219551-C Conjugates made of metal complexes and oligonucleotides SCHERING AG (DE) 2005-09-21 CN disclosed
EP-0777498-B1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES SCHERING AG (DE) 2004-04-28 EP disclosed
US-20020077306-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2002-06-20 US disclosed
CN-1152879-A Conjugates made of metal complexes and oligonucleotides SCHERING AG (DE) 1997-06-25 CN disclosed
EP-0777498-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES SCHERING AKTIENGESELLSCHAFT (DE) 1997-06-11 EP disclosed
WO-1996002274-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES SCHERING AKTIENGESELLSCHAFT (DE) 1996-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077306-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION DCLRE1B, RNASE1, DCLRE1A PPARG 4582/4885LTA4H 4191/4885POLB 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.